Лакосамид
Проводит ЮСБ Биосайенсез Инк.
Страница компанииОткрытое, многоцентровое дополнительное исследование для оценки долгосрочной безопасности и эффективности лакосамида в качестве дополнительной терапии при неконтролируемых первичных генерализованных тонико-клонических припадках у пациентов с идиопатической генерализированной эпилепсией
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/375/2015-07-15/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 4 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 50 чел. в стране «Россия».
- Центров в реестре: 7 в 7 городах. Список — ниже на странице.
- Плановая дата окончания (06.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 1 · невключение: 4
Критерии включения
- \- Subject must have completed or be an eligible Baseline failure from the parent study (SP0982 \[NCT02408523\]). Note: Other subjects screened for SP0982 may be considered for roll-over to EP0012 if the investigator considers that the subject could benefit from treatment with open-label lacosamide (LCM) and based on prior discussion with and approval from the UCB Study Physician or representative
Критерии невключения
- Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)
- Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious adverse event (SAE)
- Subject has an active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since Last Visit" version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Subject has >=2x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%). For all subjects who entered EP0012 directly with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF). Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation.
Источник: ClinicalTrials.gov, NCT02408549 · запись обновлена в реестре 14 декабря 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 36
- Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
- Number of Study Participants Withdrawn Due to TEAEs — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
- Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
- Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
- Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982) — From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Цель исследования
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects \>= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 \[NCT02408523\] study.
Области и заболевания
Где проходит
7 центров в 7 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 375 от 15.07.2015 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02408549 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.